| abstract |
The present invention provides a clear cell renal cell carcinoma (CCRcc) biomarker comprising at least 2 biomarkers selected from the group consisting of ZNF395, SMPDL3A, SLC28A1, SLC6A3, VEGFA, EGLN3, at least one of the two biomarkers being SMPDL3A or SLC28A1. The invention also relates to a detection system using the set of biomarkers according to the invention, methods for determining whether a subject has or has the recurrence of renal cell carcinoma with clear cells, methods of determining whether a kidney mass sample is benign or malignant, a method of detecting a subject's response to systemic treatment, and a kit for implementing this. |